Articles tagged "Adverse effects"

2017 American Transplant Congress
Improvement of Cyclosporine A Dosing Strategy to Enhance Medication Adherence.
M. Barten,¹ E. Harmel,¹ M. Goldmann,¹ F. Wagner,¹ H. Reichenspurner,¹ M. Rybczynski.²
¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
Background: It is known that the number of daily pills is crucial for medical adherence of patients after heart transplantation (HTx). For cyclosporine A (CsA)…
2017 American Transplant Congress
This is Why We Can't Have Nice Things- Real World Experience with Everolimus in Livers.
C. Perez,¹ J. Fleming,¹ M. Sell,¹ B. O'Brien,¹ A. Rogers,¹ I. Lee,¹ C. Mardis,¹ A. Mardis,¹ N. Patel,¹ H. Meadows,¹ N. Pilch,² K. Chavin,² D. Dubay,² D. Taber.²
¹Pharmacy, Medical University of South Carolina, Chareleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC
Purpose: To determine if discontinuation rates of everolimus (RAD) in clinical practice is higher than the 30% demonstrated in trials.Methods: This was a retrospective cohort…
2017 American Transplant Congress
An Investigation of Biopsy-Proven De Novo Autoimmune Hepatitis After Hepatitis C Clearance with Direct Acting Antivirals in Liver Transplant Patients.
R. Sigireddi, J. Moffett, M. Kueht, R. Ackah, A. Rana, C. O'Mahony, J. Goss, S. Dhingra, S. Khaderi.
Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX
Direct acting antivirals (DAAs) for hepatitis C virus (HCV) have been widely prescribed to post-liver transplant patients for HCV clearance and are believed to be…
2017 American Transplant Congress
De Novo Low-Dose Sirolimus versus Mycophenolate Mofetil in Combination with Extended-Release Tacrolimus in Kidney Transplant Recipients.
J. Lee,¹ K. Huh,¹ J. Ha,² C.-K. Oh,³ M. Ju,⁴ C.-D. Kim,⁵ H. Cho,⁶ C. Jung,⁷ B. Lim,⁸ Y. Kim.¹
¹Transplantation Surgery, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea; ²Surgery, Seoul National University Hospital, Seoul, Republic of Korea; ³Surgery, Ajou University Hospital, Suwon, Republic of Korea; ⁴Surgery, Gangnam Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea; ⁵Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea; ⁶Surgery, Ulsan University Hospital, Ulsan, Republic of Korea; ⁷Surgery, Korea University Anam Hospital, Seoul, Republic of Korea; ⁸Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea
Previous studies reported that tacrolimus (TAC) with high-dose sirolimus (SRL) was associated with worse outcomes in kidney transplantation, compared to TAC with mycophenolate mofetil (MMF.).…
2016 American Transplant Congress
A Novel Inflammation-Targeting Tacrolimus Hydrogel for Liver Transplantation.
J. Jia,¹ J. Li,¹² Y. Zhou,¹ L. Jiang,¹ J. Zhang,¹ H. Lu,¹ H. Xie,¹ L. Zhou,¹ P. Kumur,³ S. Zheng.¹²
¹Key Laboratory of Combined Multiorgan Transplantation, Ministry of Public Health, Hangzhou, China; ²Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; ³Division of Biomedical Engineering and Department of Medicine, Brigham and Women's Hospital, Boston.
Background:Immunosuppressant have played a critical role for improving graft survival after liver transplantation (LT). While long-term systemic use of immunosuppressant such as tacrolimus (FK506) is…
2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
H. Ishida,¹ K. Tanabe,¹ S. Takahara,² N. Amada,³ K. Takahashi,⁴ H. Toma.⁵
¹Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; ²Advanced Technology for Transplantation, Osaka University, Osaka, Japan; ³Surgery, JCHO Sendai Hospital, Sendai, Japan; ⁴Niigata Organ Transplant Foundation, Niigata, Japan; ⁵Urology, Toda Chuo Hospital, Toda, Saitama, Japan.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…
2016 American Transplant Congress
Telemedicine to Reduce Readmissions Post Liver Transplant: Compliance and Feasibility Results.
T. Kaiser,¹ P. Kimmel,² S. Osborn,² S. Diersing,² B. Boswell,² J. Huff,² J. Garrett,¹ N. Anwar,¹ S. Shah.¹
¹Medicine, University of Cincinnati, Cincinnati, OH; ²Transplant, University of Cincinnati Medical Center, Cincinnati, OH.
Telemedicine (TM) was added to our care model as a mechanism to reduce readmissions post liver transplant (LTx). Establishing a TM home allows for remote…
2016 American Transplant Congress
Predicting and Reducing 30-Day Readmission After Liver Transplant (OLT).
K. Eid, M. Elshamy, L. Louwers, B. Eghtesad, C. Quintini, K. Snyder, F. Aucejo, K. Hashimoto, M. Fujiki, C. Miller, D. Kelly.
Transplant Surgery, Cleveland Clinic Foundation, Cleveland, OH.
Background:Reducing early readmissions is a challenge. This study aimed to identify predictors of 30-day readmissions and interventions to minimize readmissions.Methods: Records of 523 adult OLT…
2016 American Transplant Congress
Outcomes of Untreated Asymptomatic Bacteriuria in Renal Transplant Recipients: A Single-Center Experience.
W. Davis, R.-A. Lee, L. Daniels, S. Todd, K. True, P. Chong.
University of North Carolina Medical Center, Chapel Hill, NC.
Background. Renal transplant recipients (RTR) with asymptomatic bacteriuria (AB) are often treated with antibiotics. This could lead to complications related to antibiotic treatment including Clostridium…
2016 American Transplant Congress
Schisandra Sphenanthera Extract Facilitates Anti-Tuberculosis Treatment Post Renal Transplantation Through Increasing Bioavailability of Tacrolimus.
R. Deng,¹ L. Zhang,¹ L. Liu,¹ H. Fu,² J. Li,¹ Q. Fu,¹ C. Wang.¹
¹Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; ²Infectious Medicine Department, Guangzhou Infectious Disease Hospital, Guangzhou, China.
Background: Hepatoprotective agent Schisandra sphenanthera extract (SchE) facilitates rifampicin-containing anti-tuberculosis (TB) chemotherapy by stabilizing the Tacrolimus (FK506) blood concentration through increasing the oral bioavailability, which…